Physician profile
Xin Yao
NPI 1174670145
$1,832.75
in general payments reported to CMS, 2019-2025
14 companies · $93.05 in 2025
The $93.05 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.68 · 2021: $115 · 2022: $171 · 2023: $327 · 2024: $1,041 · 2025: $93.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.66 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.90 | 2022-2024 | Imfinzi |
| Janssen Biotech, INC. | $247.94 | 2024 | Darzalex, Tecvayli |
| Tempus Ai, INC | $149.62 | 2024 | Xt Cdx |
| Astellas Pharma US INC | $146.56 | 2023-2025 | Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $118.40 | 2024 | Keytruda |
| Sobi, INC | $110.29 | 2023 | |
| Abbvie INC. | $102.97 | 2021 | |
| Rigel Pharmaceuticals, INC. | $99.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.68 | 2019 | |
| Pfizer INC. | $69.04 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.21 | 2023 | |
| Beigene USA, INC. | $30.91 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $29.69 | 2023 | Enhertu |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.